Optical Frequency Domain Imaging for Non-melanoma Skin Cancers
The purpose of this research study is to find out if a non-invasive imaging device called Optical Frequency Domain Imaging (OFDI) can help doctors to see the tissue and blood vessels that are related to non-melanoma skin cancers. OFDI was designed to see microscopic details of your skin without needing to use any invasive techniques such as surgery or biopsy.
NCT01662713 — Non-Melanoma Skin Cancer (NMSC)
Status: Completed
http://inclinicaltrials.com/non-melanoma-skin-cancer-nmsc/NCT01662713/
Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer
This case series will assess the use of suction blister epidermal grafts harvested by a novel device on select patients that have wounds from Mohs or excisional surgery.
NCT01536444 — Neoplasm of Skin
Status: Recruiting
http://inclinicaltrials.com/neoplasm-of-skin/NCT01536444/
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
The purpose of this study is to determine whether a skin cancer prevention website is effective at reduce female teenagers' desire to use indoor tanning and ultimately their use of indoor tanning over an 18 month period.
NCT01508013 — Skin Cancer
Status: Enrolling by invitation
http://inclinicaltrials.com/skin-cancer/NCT01508013/
Skin Cancer Prevention in a Pediatric Population
Skin cancer risk is largely determined by sun exposure during childhood. This study determines the effectiveness of a mailed intervention designed to increase sun protection for children age 6-9 years old. The intervention includes newsletters for parents that include risk information tailored to each child. Also included are sun protection resources such as a swim shirt, a sun hat, and sunscreen. Participants receive the intervention over 3 consecutive years, and data collection includes telephone interviews and skin exams. The study hypothesis is that receipt of the intervention will result in improved sun protection of the child.
NCT01464957 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT01464957/
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Human Basal Cell Carcinomas (BCCs) can be ablated by treating them with nanosecond pulsed electric fields (nsPEF)
NCT01463709 — Basal Cell Carcinomas
Status: Completed
http://inclinicaltrials.com/basal-cell-carcinomas/NCT01463709/
A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer
This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
NCT01459666 — Scar
Status: Terminated
http://inclinicaltrials.com/scar/NCT01459666/
Experience of Patients With Non-Melanoma Skin Cancer of the Head and Neck Undergoing Mohs Surgery
Mohs surgery excises non-melanoma skin cancer tumors of the head and neck while preserving maximum healthy tissue, an advantageous characteristic when dealing with the cosmetic and functional cervifacial region. Yet, treatment can result in changes to function and appearance with effects on quality of life. This project uses Grounded Theory to explore the Mohs surgery experience of NMSC patients who have head and neck lesions through interview and observation of the surgical appointment.
NCT01452984 — Non-Melanoma Skin Cancer
Status: Completed
http://inclinicaltrials.com/non-melanoma-skin-cancer/NCT01452984/
A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma
The aim of this study is to see if a drug called nilotinib (Tasigna®) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called cKIT. Nilotinib interferes with signalling inside cells with this mutation and it is believed that this may lead to shrinkage of tumours. Acral melanomas are found on the palms and soles and mucosal melanomas start inside body cavities rather than on the skin.
NCT01395121 — Acral Lentiginous Malignant Melanoma
Status: Completed
http://inclinicaltrials.com/acral-lentiginous-malignant-melanoma/NCT01395121/
Melanoma Risk Assessment and Skin Cancer Awareness, Prevention, and Education in a Primary Care Setting
The investigators are conducting a study to provide evidence about the comparative effectiveness of mailed, tailored intervention materials on cancer prevention behavioral outcomes. The investigators will send out three (3) tailored mailings for participants who are assigned to the intervention group. Second, during the eligibility screening, the investigators will be assessing the relative yield and functioning of two risk assessment tools (BRAT and FEARS) on determining an individual's level of risk for skin cancer.
NCT01356771 — Melanoma
Status: Completed
http://inclinicaltrials.com/melanoma/NCT01356771/
Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of the microprocessor complex subunit DGCR8 and the RISC components TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT in epithelial skin cancer and its premalignant stage.
NCT01345760 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT01345760/